Using ribosomal RNA disruption as a predictor of early relapse in canine lymphoma

** Please note this study is closed/completed and no longer recruiting patients ** 

---

Publication:
Parissenti, A. M., Pritzker, L. B., Guo, B., Narendrula, R., Wang, S. X., Lin, L. L., Pei, J., Skowronski, K., Bienzle, D., Woods, J. P., Pritzker, K., & Coomber, B. L. (2019). RNA disruption indicates CHOP therapy efficacy in canine lymphoma. BMC veterinary research, 15(1), 453. https://doi.org/10.1186/s12917-019-2189-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916446/

For REFERENCE ONLY:

Information for Clients

Information for Clinicians

Contact:

Vicky Sabine (PhD), Clinical Research Coordinator, OVC
Email: ovc.clinicaltrials@uoguelph.ca; Work Cell #: 226-218-0338

Funded by OVC Pet Trust.

<Back to Closed & Completed Trials